Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 2 098 GBX -1.41% Market Closed
Market Cap: 4.7B GBX
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one HIK stock under the Base Case scenario is hidden GBX. Compared to the current market price of 2 098 GBX, Hikma Pharmaceuticals PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2
P/S
P/S
Price to Sales
2
vs History
44
vs Industry
54
Median 3Y
1.9
Median 5Y
2
Industry
2.6
Forward
0
More Details
17.6
P/E
P/E
Price to Earnings
17.6
vs History
38
vs Industry
30
Median 3Y
19.7
Median 5Y
16.8
Industry
21.5
Forward
0.1
More Details
11.2
P/OCF
P/OCF
Price to OCF
11.2
vs History
28
vs Industry
37
Median 3Y
8.9
Median 5Y
9.7
Industry
16.6
More Details
17.3
P/FCFE
P/FCFE
Price to FCFE
17.3
vs History
50
vs Industry
25
Median 3Y
18.2
Median 5Y
18.2
Industry
24
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
31
vs Industry
30
Median 3Y
2.4
Median 5Y
2.5
Industry
2.1
More Details
16.6
EV/S
EV/S
Enterprise Value to Sales
16.6
vs History
76
vs Industry
7
Median 3Y
31.3
Median 5Y
26
Industry
2.7
Forward
0.2
More Details
36.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
36.3
vs History
76
vs Industry
3
Median 3Y
65.5
Median 5Y
50.2
Industry
5.3
More Details
65.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
65.9
vs History
76
vs Industry
2
Median 3Y
102.3
Median 5Y
95.7
Industry
12.8
Forward
0.6
More Details
83.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
83.5
vs History
76
vs Industry
3
Median 3Y
151.7
Median 5Y
115.5
Industry
16.2
Forward
0.7
More Details
93.1
EV/OCF
EV/OCF
Enterprise Value to OCF
93.1
vs History
66
vs Industry
3
Median 3Y
160.3
Median 5Y
148.2
Industry
14.9
More Details
159.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
159.6
vs History
66
vs Industry
2
Median 3Y
247
Median 5Y
247
Industry
17.7
More Details
11.5
EV/IC
EV/IC
Enterprise Value to IC
11.5
vs History
76
vs Industry
5
Median 3Y
23.2
Median 5Y
17.3
Industry
1.9
More Details

Multiples Across Competitors

HIK Competitors Multiples
Hikma Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.7B GBP 2 17.6 65.9 83.5
US
Eli Lilly and Co
NYSE:LLY
765.4B USD 15.6 68.9 37 40.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.3 21.1 14.6 16.7
CH
Roche Holding AG
SIX:ROG
209.1B CHF 3.5 25.3 9.5 11.1
CH
Novartis AG
SIX:NOVN
188.8B CHF 4.4 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
167.7B GBP 4.1 29.3 131.2 197.8
US
Merck & Co Inc
NYSE:MRK
203.7B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
138.7B USD 2.2 17.6 7.5 10.6
P/E Multiple
Earnings Growth PEG
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average P/E: 25.2
17.6
20%
0.9
US
Eli Lilly and Co
NYSE:LLY
68.9
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.1
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.3
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.6
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average EV/EBITDA: 400.5
65.9
9%
7.3
US
Eli Lilly and Co
NYSE:LLY
37
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average EV/EBIT: 1 705.4
83.5
12%
7
US
Eli Lilly and Co
NYSE:LLY
40.4
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16.7
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.8
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
10%
1.1

See Also

Summary
HIK intrinsic value, competitors valuation, and company profile.
DCF Valuation
HIK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HIK stock valuation using valuation multiples.
Wall Street Estimates
HIK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HIK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.